If environmental factors such as enteroviruses can trigger beta-cell autoimmunity, then is it possible that a vaccine can reduce the likelihood of developing type 1 diabetes?

The study findings demonstrate a balance between cardiovascular protection and major bleeding. 

How does diabetes affect the risk of developing late-life mild cognitive impairment or dementia?  

Results from the recently published PIONEER trial series demonstrate the overall diabetic benefits of oral semaglutide, a novel GLP-1 receptor agonist. 

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

New study findings challenge the link between neuropathic pain and vitamin D levels in people with type 2 diabetes.

Could older recommendations of maintaining a blood pressure of 140/90 mmHg be misleading in younger adults with type 1 diabetes for cardiovascular risk reduction? 

The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.

Why having a high bone mineral density may not always decrease the risk of fractures.